SAN
DIEGO, April 25, 2024 /PRNewswire/
-- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme")
today announced the election of Mahesh
Krishnan, M.D. to its Board of Directors. Dr. Krishnan has
more than 20 years of experience in healthcare, biotechnology and
health services.
"Mahesh is a dynamic and highly accomplished healthcare
executive, and we are pleased to welcome him to the Halozyme
board," said Dr. Helen Torley,
president and chief executive officer. "His experience with
building and growing business opportunities in addition to his
medical expertise, will provide valuable perspective as we expand
our leadership as the premier provider of innovative drug delivery
technologies."
Dr. Krishnan currently serves as Group Vice President of Growth
at DaVita, Inc., one of the largest providers of kidney care
services in the U.S. He was co-lead of the DaVita Venture Group,
where he oversaw strategic partnerships in technology and research
and development within the organization. In his current role, he
also oversees aspects of medical policy in Washington, D.C. Dr. Krishnan previously
served as DaVita's Group Vice President of Research and Development
and was the company's first international Chief Medical Officer.
Prior to DaVita, he served in various roles at Amgen Inc.,
including as the Global Development Leader for Epogen® and
Executive Director, Medical Policy for all of Amgen's domestic
products. Prior to his time at Amgen, Dr. Krishnan was a practicing
nephrologist at Virginia Nephrology Group.
"I am honored to join Halozyme as a board member at such an
exciting time for their business," said Dr. Krishnan. "As
they continue to innovate with their disruptive drug delivery
technologies and execute their patient centric vision, I look
forward to leveraging my background and sharing my expertise to
support their growth."
Dr. Krishnan earned his B.S. in pre-medicine from The
Pennsylvania State University and M.D.
from Jefferson Medical College at Thomas
Jefferson University. He also holds an M.P.H. from
Johns Hopkins University and an M.B.A.
in healthcare management from the Johns Hopkins Carey School of
Business.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive
solutions to improve patient experiences and outcomes for emerging
and established therapies. As the innovators of ENHANZE® drug
delivery technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the
subcutaneous delivery of injected drugs and fluids, with the goal
of reducing treatment burden for patients. Having touched more than
800,000 patient lives in post-marketing use in seven commercialized
products across more than 100 global markets, Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and biotechnology
companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli
Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai
Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technologies that are designed to provide
commercial or functional advantages such as improved convenience,
reliability and tolerability, and enhanced patient comfort and
adherence. The Company has two commercial proprietary products,
Hylenex® and XYOSTED®, partnered commercial products and ongoing
product development programs with several pharmaceutical companies
including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release may include forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts and may include projections and estimates and
their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future
financial results, events, operations, services, product
development and potential and statements regarding future
performance and growth of Halozyme's business. Forward-looking
statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans", "will
be" and similar expressions and include statements in this press
release related to Halozyme's intention to redeem all of the
outstanding Notes. Although Halozyme believes that the expectations
reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of
Halozyme, that could cause actual results and developments to
differ materially from those expressed in the forward-looking
information and statements. Actual results could differ materially
from the expectations contained in these forward-looking statements
as a result of several factors. These and other factors that may
result in differences are discussed in greater detail in the
Company's most recently filed Annual Report on Form 10-K filed with
the Securities and Exchange Commission. Halozyme undertakes no
obligation to update or revise any forward-looking statements or
any other information contained herein.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
617-877-9710
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mahesh-krishnan-elected-to-halozymes-board-of-directors-302127757.html
SOURCE Halozyme Therapeutics, Inc.